<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03281005</url>
  </required_header>
  <id_info>
    <org_study_id>CRE170041</org_study_id>
    <nct_id>NCT03281005</nct_id>
  </id_info>
  <brief_title>Development of Visual Function Evaluation Method</brief_title>
  <official_title>Calibration of Visual Function Evaluation Tests in Patients With Severe Vision Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to develop the comprehensive visual function evaluation method
      in severe visually impaired patient
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective observational study which consists of 4 Parts; Part 1A, 1B, 2 and
      3. Part 1A has been conducted on 6 subjects diagnosed with retinitis pigmentosa. Additional
      examination will be performed using alternative devices imported outside Japan on subjects
      who completed Part 1A and re-consented (Part 1B). Based on the interim result of Part 1A,
      Part 2 will be conducted on another 6 subjects with retinitis pigmentosa with improved
      methodology and the devices used in Part 1B. Part 3 will be conducted in 6 healthy volunteers
      to obtain comparative data using devices used in Part 1B.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Slit-lamp microscopy in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slit-lamp microscopy in Part 1B and 3</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optical Coherence Tomography (OCT) test in Part 1A and 2</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity test with Early Treatment Diabetic Retinopathy Study (ETDRS) in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity test with ETDRS in Part 1B</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function and the quality of life (QOL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The 11-item National Eye Institute Visual Function Questionnaire (NEI VFQ-11) in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function and QOL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nottingham Adjustment Scale Japanese Version (NAS-J) in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the psychological adjustment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily living task dependent on vision (DLTV) in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess QOL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Table test in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metropsis test in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Low vision evaluator (LoVE) in Part 1A</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White flash visual evoked potential (VEP) test in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White flash VEP test in Part 1B and 3</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Color flash VEP test in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Color flash VEP test in Part 1B and 3</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrically evoked response (EER) test in Part 1A and 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EER test in Part 1B and 3</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White flash electroretinography test in Part 1A, 1B, 2 and 3</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupillary function test in Part 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupillary function test in Part 1B and 3</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Full field stimulus threshold testing (FST) in Part 2</measure>
    <time_frame>Up to week 8</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FST in Part 1B</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Retinitis pigmentosa in Part 1A</arm_group_label>
    <description>Retinitis pigmentosa patients with severe visual impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinitis pigmentosa in Part 1B</arm_group_label>
    <description>Retinitis pigmentosa patients with severe visual impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinitis pigmentosa in Part 2</arm_group_label>
    <description>Retinitis pigmentosa patients with severe visual impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers in Part 3</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Retinitis pigmentosa, healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for patients with retinitis pigmentosa:

          -  Age: ≥ 20 years

          -  Subjects with severe visual disturbance (count-fingers or worse vision for severe
             eyes) at the time of obtaining the consent

        Inclusion Criteria for healthy Volunteers:

          -  Age: ≥ 35 and ≤ 75 years

          -  Subjects with corrected visual acuity ≥ 1.0 with both eyes and without severe
             refractive error nor abnormal findings in slit-lamp microscopy, OCT, fundoscopy and
             pupillary function test at screening

        Exclusion Criteria:

          -  Subjects who have participated in any other clinical trial or clinical study involving
             visual function evaluation within 6 months

          -  Subjects who have history of surgery, past history, and complications (cardiac/
             hepatic/ renal/ respiratory/ hematological diseases, optic nerve diseases causing
             marked loss of visual field, and uveitis etc.) that potentially affect evaluation and
             safety of the study

          -  Pregnant women

          -  Subjects who are judged that continuation of the study is difficult during the study
             period

          -  Subjects who are employed by the company sponsoring this study, an organization or
             institution related to this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Administration Dept.</last_name>
    <email>astellas.registration@astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2017</study_first_submitted>
  <study_first_submitted_qc>September 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2017</study_first_posted>
  <last_update_submitted>May 6, 2018</last_update_submitted>
  <last_update_submitted_qc>May 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinitis pigmentosa</keyword>
  <keyword>Visual function evaluation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

